Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.
Abstract
Background
Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We evaluated real-world outcomes and associated factors.
Methods
This multicenter retrospective registry study included patients who received everolimus-based endocrine therapy after CDK4/6 inhibitor treatment. The primary endpoint was time to treatment failure (TTF). Overall survival (OS), treatment response, and exploratory post-TTF survival were also evaluated. Associations were analyzed using Firth-penalized Cox and logistic regression models.
Results
Among 169 eligible patients, median TTF and OS were 4.1 months (95% confidence interval [CI], 3.2-4.8) and 28.7 months (95% CI, 24.9-39.0), respectively. Non-ductal histology, progesterone receptor (PgR) expression <10%, and prior chemotherapy were independently associated with shorter TTF. Prior chemotherapy and metastases involving four or more organs were independently associated with shorter OS. Low PgR expression was independently associated with failure to achieve disease control and was also associated with failure to achieve objective response in univariable analysis. Post-TTF survival did not differ significantly by histologic subtype or PgR expression but was shorter in patients with prior chemotherapy or metastases involving four or more organs. Increasing numbers of adverse clinical factors were associated with progressively shorter TTF and OS.
Conclusions
Outcomes varied according to tumor characteristics, prior treatment, and metastatic burden. Histologic subtype and PgR expression were associated with treatment durability, whereas prior chemotherapy and extensive metastatic burden were associated with overall prognosis. The exploratory risk stratification based on these routinely available factors warrants external validation.